trial · primary record
Amivantamab IV
Carcinoma, Non-Small-Cell Lung
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 305 |
| Primary completion | 2030-06-30 |
| Primary endpoint | Number of Participants With Grade Greater Than or Equal to (>=) 2 Dermatologic Adverse Events of Interest (DAEIs) Within 12 Weeks After Initiation of Anticancer Treatment |
| Registry ID | NCT06120140 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:42.738Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06120140
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Amivantamab IV · compound